JP2020508334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508334A5 JP2020508334A5 JP2019546216A JP2019546216A JP2020508334A5 JP 2020508334 A5 JP2020508334 A5 JP 2020508334A5 JP 2019546216 A JP2019546216 A JP 2019546216A JP 2019546216 A JP2019546216 A JP 2019546216A JP 2020508334 A5 JP2020508334 A5 JP 2020508334A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- mab
- chain variable
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 151
- 238000009739 binding Methods 0.000 claims description 151
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 claims description 83
- AVIZABGQXBMRCJ-UHFFFAOYSA-N MAB 3 Natural products C12=C(O)C(C(=O)C(C)CC)=C3OC(C(C)(C)O)CC3=C2OC(=O)C=C1C1=CC=CC=C1 AVIZABGQXBMRCJ-UHFFFAOYSA-N 0.000 claims description 83
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 53
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 49
- YALRCXHVQYBSJC-UHFFFAOYSA-N Mammea A/AB Chemical compound C12=C(O)C(C(=O)C(C)CC)=C(O)C(CC=C(C)C)=C2OC(=O)C=C1C1=CC=CC=C1 YALRCXHVQYBSJC-UHFFFAOYSA-N 0.000 claims description 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 47
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 46
- 229920001184 polypeptide Polymers 0.000 claims description 45
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 28
- KTJYLXIAFCVVBF-UHFFFAOYSA-N MAB 4 Chemical compound C1=2CC(C(C)(C)O)OC=2C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC KTJYLXIAFCVVBF-UHFFFAOYSA-N 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 claims description 7
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 claims description 7
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Mammea B/AB Chemical compound CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 102000005962 receptors Human genes 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims 1
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 claims 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 102000015735 Beta-catenin Human genes 0.000 claims 1
- 108060000903 Beta-catenin Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 1
- 102100024210 CD166 antigen Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000049320 CD36 Human genes 0.000 claims 1
- 108010045374 CD36 Antigens Proteins 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108090000007 Carboxypeptidase M Proteins 0.000 claims 1
- 102100032936 Carboxypeptidase M Human genes 0.000 claims 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 102100030385 Granzyme B Human genes 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 101000964453 Homo sapiens Zinc finger protein 354C Proteins 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 102100033011 Integrin beta-6 Human genes 0.000 claims 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 108010040135 Junctional Adhesion Molecule C Proteins 0.000 claims 1
- 102100023429 Junctional adhesion molecule C Human genes 0.000 claims 1
- 102000005712 Keratin-8 Human genes 0.000 claims 1
- 108010070511 Keratin-8 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 102100039373 Membrane cofactor protein Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 108010008707 Mucin-1 Proteins 0.000 claims 1
- 101001009604 Mus musculus Granzyme B(G,H) Proteins 0.000 claims 1
- 101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 claims 1
- 101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 claims 1
- 108010056664 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102000004140 Oncostatin M Human genes 0.000 claims 1
- 108090000630 Oncostatin M Proteins 0.000 claims 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 claims 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- JFZHPFOXAAIUMB-UHFFFAOYSA-N Phenylethylmalonamide Chemical compound CCC(C(N)=O)(C(N)=O)C1=CC=CC=C1 JFZHPFOXAAIUMB-UHFFFAOYSA-N 0.000 claims 1
- 241001425800 Pipa Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 101800000385 Transmembrane protein Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 102100040311 Zinc finger protein 354C Human genes 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 claims 1
- 210000004251 human milk Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 11
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000000139 costimulatory effect Effects 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000000375 direct analysis in real time Methods 0.000 description 4
- 238000012063 dual-affinity re-targeting Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 229960000402 palivizumab Drugs 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 108010055196 EphA2 Receptor Proteins 0.000 description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229950003135 margetuximab Drugs 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229950003520 utomilumab Drugs 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762463353P | 2017-02-24 | 2017-02-24 | |
| US62/463,353 | 2017-02-24 | ||
| US201762597594P | 2017-12-12 | 2017-12-12 | |
| US62/597,594 | 2017-12-12 | ||
| PCT/US2018/019188 WO2018156740A1 (en) | 2017-02-24 | 2018-02-22 | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508334A JP2020508334A (ja) | 2020-03-19 |
| JP2020508334A5 true JP2020508334A5 (2) | 2021-04-01 |
| JP7132232B2 JP7132232B2 (ja) | 2022-09-06 |
Family
ID=63252984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546216A Active JP7132232B2 (ja) | 2017-02-24 | 2018-02-22 | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11459394B2 (2) |
| EP (2) | EP4389226A3 (2) |
| JP (1) | JP7132232B2 (2) |
| KR (1) | KR102585848B1 (2) |
| CN (1) | CN110325209A (2) |
| AU (1) | AU2018224094B2 (2) |
| BR (1) | BR112019017628A2 (2) |
| CA (1) | CA3053803A1 (2) |
| IL (1) | IL268836B2 (2) |
| MA (1) | MA47612A (2) |
| MX (1) | MX2019009967A (2) |
| SG (1) | SG11201907753TA (2) |
| TW (1) | TWI788327B (2) |
| WO (1) | WO2018156740A1 (2) |
| ZA (1) | ZA201905347B (2) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| MX375669B (es) * | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| GEP20227398B (en) | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| EP3445788B1 (en) | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| AU2018224094B2 (en) | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| EP3655439A1 (en) | 2017-07-20 | 2020-05-27 | Aptevo Research and Development LLC | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| TWI839395B (zh) * | 2018-10-09 | 2024-04-21 | 瑞士商Ｎｕｍａｂ治療公司 | 靶向cd137的抗體及其使用方法 |
| JP7596263B2 (ja) * | 2018-10-10 | 2024-12-09 | ザイムワークス ビーシー インコーポレイテッド | ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 |
| JP7410143B2 (ja) * | 2018-11-01 | 2024-01-09 | 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 | 二重特異性抗体及びその用途 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| WO2020225577A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
| CN120441704A (zh) | 2019-06-26 | 2025-08-08 | 圆祥生技股份有限公司 | T细胞活化抗体 |
| EP4004054A4 (en) * | 2019-07-26 | 2023-10-25 | Yuhan Corporation | ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODIES AND ITS APPLICATION |
| TWI860386B (zh) * | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| SMT202500247T1 (it) | 2019-10-03 | 2025-09-12 | Bicycletx Ltd | Complessi peptidici eterotandem biciclici |
| JP7634001B2 (ja) * | 2019-10-11 | 2025-02-20 | ナンチン リーズ バイオラブス カンパニー，リミティド | ４－１ｂｂに結合する抗体およびその用途 |
| CN110894238B (zh) * | 2019-11-25 | 2021-01-19 | 华道(上海)生物医药有限公司 | Car-t细胞的检测用单克隆抗体、试剂盒及应用 |
| CN115427059A (zh) * | 2020-01-31 | 2022-12-02 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| US12060434B2 (en) * | 2020-02-25 | 2024-08-13 | Gensun Biopharma Inc. | Trispecific T cell engagers |
| IL295434A (en) * | 2020-02-21 | 2022-10-01 | Macrogenics Inc | cd137 binding molecules and their uses |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| US20230265202A1 (en) * | 2020-04-15 | 2023-08-24 | Zymeworks Inc. | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof |
| EP4155319A4 (en) * | 2020-06-30 | 2024-06-12 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1BB BINDING PROTEIN AND ITS USE |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| CN112119977B (zh) * | 2020-10-15 | 2021-10-19 | 中国人民解放军军事科学院军事医学研究院 | Cd317诱导的抑郁和记忆损伤的小鼠模型的构建方法及其应用 |
| WO2022103705A1 (en) * | 2020-11-11 | 2022-05-19 | Versapeutics Inc. | Antibody variants against wnt receptor ryk |
| JP2024504388A (ja) * | 2021-01-25 | 2024-01-31 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| JP2025512915A (ja) * | 2022-04-07 | 2025-04-22 | ユハン コーポレーション | Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物 |
| CN117007808A (zh) * | 2022-04-27 | 2023-11-07 | 洛阳中科生物芯片技术有限公司 | 非洲猪瘟病毒CD2v蛋白阻断生物芯片抗体检测试剂盒 |
| CN115368465B (zh) * | 2022-07-19 | 2026-02-24 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| IL320949A (en) * | 2022-11-21 | 2025-07-01 | Beigene Switzerland Gmbh | Antibodies against CD137 and methods of using them |
| WO2024114676A1 (zh) * | 2022-11-29 | 2024-06-06 | 江苏恒瑞医药股份有限公司 | Cldn18.2/4-1bb结合蛋白及其医药用途 |
| CN120530142A (zh) * | 2023-01-13 | 2025-08-22 | 上海凯今生物科技有限公司 | 多特异性多肽复合物 |
| CN116693684B (zh) * | 2023-04-19 | 2025-11-04 | 浙江正熙生物技术有限公司 | 一种抗人cd8抗体及其制备方法和应用 |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| CN120795136B (zh) * | 2025-09-11 | 2025-12-09 | 华中农业大学 | 猪德尔塔冠状病毒单克隆抗体及其在制备抗原检测试纸条中的应用 |
Family Cites Families (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5843749A (en) | 1991-07-26 | 1998-12-01 | Regeneron Pharmaceuticals, Inc. | Ehk and Ror tyrosine kinases |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| EP0846571B1 (en) | 1996-12-04 | 2001-04-11 | Agfa-Gevaert N.V. | Method for the formation of an improved heat mode image |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6852703B1 (en) | 1997-06-04 | 2005-02-08 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
| AU1490801A (en) | 1999-11-15 | 2001-05-30 | University Of Southern California | Targeted delivery of therapeutic and diagnostic moieties |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| EP1319184B1 (en) | 2000-08-14 | 2007-07-25 | N.V. Organon | Use of antibodies against specific mhc-peptide complexes |
| US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
| US8501471B2 (en) | 2000-10-18 | 2013-08-06 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US7666424B2 (en) | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
| US7740845B2 (en) | 2000-10-18 | 2010-06-22 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US8414892B2 (en) | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
| US20030138425A1 (en) | 2001-09-21 | 2003-07-24 | Mather Jennie Powell | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
| US7651686B2 (en) | 2001-10-09 | 2010-01-26 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by 4-1bb-binding agents |
| US7148038B2 (en) | 2001-10-16 | 2006-12-12 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof |
| CA2481922A1 (en) | 2002-04-12 | 2003-10-23 | Raven Biotechnologies, Inc. | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
| US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
| US20040048319A1 (en) | 2002-05-03 | 2004-03-11 | Mather Jennie P. | ALCAM and ALCAM modulators |
| ATE525398T1 (de) | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
| ATE488530T1 (de) | 2002-06-19 | 2010-12-15 | Raven Biotechnologies Inc | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel |
| US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7405061B2 (en) | 2002-11-13 | 2008-07-29 | Raven Biotechnologies, Inc. | Antigen PIPA and antibodies that bind thereto |
| EP1575672A2 (en) | 2002-12-16 | 2005-09-21 | Herbert Schwarz | Use of cd137 antagonists for the treatment of tumors |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| KR100500283B1 (ko) * | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
| CN101048425B (zh) | 2003-09-18 | 2012-12-26 | 雷文生物技术公司 | Kid3及与其结合的kid3抗体 |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| DK1709081T3 (da) | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| JP4824025B2 (ja) | 2004-06-07 | 2011-11-24 | マクロジェニックス ウエスト，インコーポレイテッド | トランスフェリンレセプター抗体 |
| CA2583741C (en) | 2004-10-15 | 2014-10-14 | Verisign, Inc. | An algorithm to create and validate a one time password |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7687242B2 (en) | 2005-01-12 | 2010-03-30 | Raven Biotechnologies, Inc. | KID31 and antibodies that bind thereto |
| US7847070B2 (en) | 2005-01-31 | 2010-12-07 | Raven Biotechnologies, Inc. | LUCA2 and antibodies that bind thereto |
| WO2006084075A2 (en) | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Adam-9 modulators |
| US20060171952A1 (en) | 2005-02-02 | 2006-08-03 | Mather Jennie P | JAM-3 and antibodies that bind thereto |
| US7572896B2 (en) | 2005-02-03 | 2009-08-11 | Raven Biotechnologies, Inc. | Antibodies to oncostatin M receptor |
| CN101155830B (zh) | 2005-02-04 | 2014-06-18 | 雷文生物技术公司 | 结合epha2的抗体及其使用方法 |
| US20080019905A9 (en) | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
| US20060182744A1 (en) | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| ES2971647T3 (es) | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2607056C (en) | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| SG153825A1 (en) | 2005-12-16 | 2009-07-29 | Ibc Pharmaceuticals Inc | Multivalent immunoglobulin-based bioactive assemblies |
| DK2368914T3 (en) | 2006-03-10 | 2019-03-04 | Wyeth Llc | Anti-5T4 antibodies and uses thereof |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| US8350011B2 (en) | 2006-08-04 | 2013-01-08 | Medimmune Limited | Antibodies to ErbB2 |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US20100143245A1 (en) | 2007-03-22 | 2010-06-10 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8h9 |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| WO2009033095A2 (en) | 2007-09-07 | 2009-03-12 | Cisthera, Incorporated | Humanized pai-1 antibodies |
| US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
| ES2589912T3 (es) | 2008-04-02 | 2016-11-17 | Macrogenics, Inc. | Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos |
| WO2009123894A2 (en) | 2008-04-02 | 2009-10-08 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| US20110081347A1 (en) | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2010027797A1 (en) | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| WO2010028795A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2010028796A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
| WO2010028797A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| JP2010249130A (ja) | 2009-03-27 | 2010-11-04 | Sanden Corp | 流体機械 |
| PE20120540A1 (es) | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| DE102009040716B4 (de) | 2009-09-10 | 2011-07-14 | Miltenyi Biotec GmbH, 51429 | Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen |
| EP2478110B1 (en) | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| SG181533A1 (en) | 2009-12-07 | 2012-07-30 | Univ Leland Stanford Junior | Methods for enhancing anti-tumor antibody therapy |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US8876892B2 (en) | 2010-04-21 | 2014-11-04 | Medtronic, Inc. | Prosthetic heart valve delivery system with spacing |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
| CA2800769C (en) * | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| EP2596114A4 (en) | 2010-07-14 | 2014-01-08 | Amgen Inc | IMMUNOGLOBULIN WITH DOMAIN INSERTION |
| AU2011286024B2 (en) | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| US9803210B2 (en) | 2011-02-11 | 2017-10-31 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
| PT2691112T (pt) | 2011-03-31 | 2018-07-10 | Merck Sharp & Dohme | Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| WO2012147713A1 (ja) | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体 |
| ES2703780T3 (es) | 2011-05-17 | 2019-03-12 | Trion Res Gmbh | Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno |
| BR112013029892A2 (pt) | 2011-05-21 | 2016-12-20 | Macrogenics Inc | polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada |
| KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| WO2012162583A1 (en) | 2011-05-26 | 2012-11-29 | Ibc Pharmaceuticals, Inc. | Design and construction of novel multivalent antibodies |
| WO2013003647A2 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
| US20140155581A1 (en) | 2011-07-06 | 2014-06-05 | Medimmune, Llc | Methods For Making Multimeric Polypeptides |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| JP6060162B2 (ja) | 2011-08-23 | 2017-01-11 | ロシュ グリクアート アーゲー | ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| CA2846432A1 (en) | 2011-09-23 | 2013-03-28 | Amgen Research (Munich) Gmbh | Bispecific binding molecules for 5t4 and cd3 |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| MX2014014162A (es) | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| EP2961770A1 (en) | 2013-02-26 | 2016-01-06 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| WO2014137931A1 (en) | 2013-03-06 | 2014-09-12 | Imaginab, Inc. | Antigen binding constructs to 5t4 |
| SMT202100464T1 (it) | 2013-03-14 | 2021-11-12 | Macrogenics Inc | Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| KR101453462B1 (ko) * | 2013-05-16 | 2014-10-23 | 앱클론(주) | Her2에 특이적으로 결합하는 항체 |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| UA116479C2 (uk) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ |
| EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| PL3094351T3 (pl) | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| AU2015244814B2 (en) * | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| RU2715038C2 (ru) | 2014-07-11 | 2020-02-21 | Дженентек, Инк. | Антитела анти-pd-l1 и способы их диагностического применения |
| BR112017001385B1 (pt) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão |
| WO2016022939A1 (en) | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| MA40609B1 (fr) | 2014-09-05 | 2020-05-29 | Janssen Pharmaceutica Nv | Agents de liaison cd123 et leurs utilisations |
| MX375669B (es) | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| WO2016073860A1 (en) * | 2014-11-06 | 2016-05-12 | Medimmune, Llc | Binding molecules specific for staphylococcus protein a and uses thereof |
| EP3218409A2 (en) | 2014-11-11 | 2017-09-20 | Sutro Biopharma, Inc. | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| DK3237446T3 (en) | 2014-12-22 | 2021-07-26 | Pd 1 Acquisition Group Llc | Anti-PD-1-antistoffer |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| KR20180016972A (ko) | 2015-02-22 | 2018-02-20 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd137에 결합하는 항체 치료제 |
| US20160257761A1 (en) | 2015-03-06 | 2016-09-08 | Macrogenics, Inc. | HER2/neu-Specific Antibodies and Methods of Using Same |
| JP6783797B2 (ja) * | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| BR112017023943A2 (pt) | 2015-05-08 | 2018-07-31 | Xencor, Inc. | anticorpos heterodimêricos que ligam cd3 e antígenos de tumor |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| HUE065109T2 (hu) | 2015-06-26 | 2024-05-28 | Celgene Corp | Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| US11236159B2 (en) * | 2015-08-03 | 2022-02-01 | Novartis Ag | Methods of treating FGF21-associated disorders |
| US20190002563A1 (en) | 2015-08-17 | 2019-01-03 | Macrogenics, Inc. | Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| US20180346571A1 (en) | 2015-11-17 | 2018-12-06 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| KR20180097615A (ko) | 2016-01-08 | 2018-08-31 | 에프. 호프만-라 로슈 아게 | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| WO2017142928A1 (en) | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| ES2981272T3 (es) | 2016-09-23 | 2024-10-08 | Merus Nv | Moléculas de unión que modulan una actividad biológica expresada por una célula |
| AU2018224094B2 (en) * | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| AU2018348431B2 (en) | 2017-10-10 | 2025-10-02 | Numab Therapeutics AG | Antibodies targeting CD137 and methods of use thereof |
| US12202911B2 (en) | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| WO2019104716A1 (en) | 2017-12-01 | 2019-06-06 | Adagene Inc. | Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody |
| JP7059388B2 (ja) | 2018-03-23 | 2022-04-25 | イーライ リリー アンド カンパニー | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 |
-
2018
- 2018-02-22 AU AU2018224094A patent/AU2018224094B2/en active Active
- 2018-02-22 EP EP24171071.4A patent/EP4389226A3/en active Pending
- 2018-02-22 SG SG11201907753TA patent/SG11201907753TA/en unknown
- 2018-02-22 IL IL268836A patent/IL268836B2/en unknown
- 2018-02-22 CA CA3053803A patent/CA3053803A1/en active Pending
- 2018-02-22 MX MX2019009967A patent/MX2019009967A/es unknown
- 2018-02-22 BR BR112019017628-4A patent/BR112019017628A2/pt unknown
- 2018-02-22 US US16/488,025 patent/US11459394B2/en active Active
- 2018-02-22 MA MA047612A patent/MA47612A/fr unknown
- 2018-02-22 CN CN201880013509.6A patent/CN110325209A/zh active Pending
- 2018-02-22 WO PCT/US2018/019188 patent/WO2018156740A1/en not_active Ceased
- 2018-02-22 KR KR1020197027622A patent/KR102585848B1/ko active Active
- 2018-02-22 JP JP2019546216A patent/JP7132232B2/ja active Active
- 2018-02-22 EP EP18757875.2A patent/EP3585431A4/en not_active Withdrawn
- 2018-02-23 TW TW107106261A patent/TWI788327B/zh not_active IP Right Cessation
-
2019
- 2019-08-13 ZA ZA2019/05347A patent/ZA201905347B/en unknown
-
2022
- 2022-08-08 US US17/883,158 patent/US11942149B2/en active Active
-
2024
- 2024-02-15 US US18/442,857 patent/US20240233818A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508334A5 (2) | ||
| JP2022137054A (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| JP2020103301A5 (2) | ||
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| US20230391882A1 (en) | Combination treatment | |
| JP2020536543A5 (2) | ||
| EP3816185A1 (en) | Multispecific antibody directed against pd-l1 and a tumor-associated antigen | |
| JP2021506244A5 (2) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| IL268836B1 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| JP2017535257A5 (2) | ||
| JP2019500891A5 (2) | ||
| US12312409B2 (en) | Bispecific CD137-binding antibodies for T-cell activation | |
| TWI806088B (zh) | 具有H2L2與HCAb結構的結合蛋白 | |
| JP2024518200A (ja) | Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物 | |
| AU2017206618A1 (en) | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent | |
| JP2021523949A5 (2) | ||
| JP2024523838A5 (2) | ||
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JP2022502079A5 (2) | ||
| WO2024085166A1 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| RU2026106661A (ru) | Анти-b7-h3 антитела и их применения | |
| JP2025508963A5 (2) | ||
| HK40082471A (en) | Binding protein having h2l2 and hcab structures | |
| RU2024137468A (ru) | Антитело и его применение |